Your browser doesn't support javascript.
loading
Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients.
Powers, John H; Bacci, Elizabeth D; Guerrero, M Lourdes; Leidy, Nancy Kline; Stringer, Sonja; Kim, Katherine; Memoli, Matthew J; Han, Alison; Fairchok, Mary P; Chen, Wei-Ju; Arnold, John C; Danaher, Patrick J; Lalani, Tahaniyat; Ridoré, Michelande; Burgess, Timothy H; Millar, Eugene V; Hernández, Andrés; Rodríguez-Zulueta, Patricia; Smolskis, Mary C; Ortega-Gallegos, Hilda; Pett, Sarah; Fischer, William; Gillor, Daniel; Macias, Laura Moreno; DuVal, Anna; Rothman, Richard; Dugas, Andrea; Ruiz-Palacios, Guillermo M.
Afiliación
  • Powers JH; Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, USA. Electronic address: john.powers@nih.gov.
  • Bacci ED; Evidera, Seattle, WA, USA.
  • Guerrero ML; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Leidy NK; Evidera, Bethesda, MD, USA.
  • Stringer S; Evidera, Bethesda, MD, USA.
  • Kim K; Evidera, Bethesda, MD, USA.
  • Memoli MJ; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Han A; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Fairchok MP; Madigan Army Medical Center, Fort Lewis, WA, USA; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advan
  • Chen WJ; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
  • Arnold JC; Naval Medical Center, San Diego, CA, USA.
  • Danaher PJ; Defense Institute for Medical Operations, San Antonio, TX, USA.
  • Lalani T; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; Naval Medical Center, Portsmouth, VA, USA.
  • Ridoré M; Children's National Medical Center, Washington, DC, USA.
  • Burgess TH; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Millar EV; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
  • Hernández A; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.
  • Rodríguez-Zulueta P; Hospital General Dr. Manuel Gea González, Mexico City, Mexico.
  • Smolskis MC; Evidera, Bethesda, MD, USA.
  • Ortega-Gallegos H; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Pett S; University College London, London, UK; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Fischer W; University of North Carolina, Chapel Hill, NC, USA.
  • Gillor D; Cologne, Germany.
  • Macias LM; Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina.
  • DuVal A; Johns Hopkins University School of Medicine, Baltimore, MD, USA (for the INSIGHT Flu 002 Plus Writing Group, the México Emerging Infectious Diseases Clinical Research Network, and the Infectious Diseases Clinical Research Program).
  • Rothman R; Johns Hopkins University School of Medicine, Baltimore, MD, USA (for the INSIGHT Flu 002 Plus Writing Group, the México Emerging Infectious Diseases Clinical Research Network, and the Infectious Diseases Clinical Research Program).
  • Dugas A; Johns Hopkins University School of Medicine, Baltimore, MD, USA (for the INSIGHT Flu 002 Plus Writing Group, the México Emerging Infectious Diseases Clinical Research Network, and the Infectious Diseases Clinical Research Program).
  • Ruiz-Palacios GM; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Value Health ; 21(2): 210-218, 2018 02.
Article en En | MEDLINE | ID: mdl-29477403
OBJECTIVES: To assess the reliability, validity, and responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) scores for quantifying the presence and severity of influenza symptoms. METHODS: An observational prospective cohort study of adults (≥18 years) with influenza-like illness in the United States, the United Kingdom, Mexico, and South America was conducted. Participants completed the 37-item draft FLU-PRO daily for up to 14 days. Item-level and factor analyses were used to remove items and determine factor structure. Reliability of the final tool was estimated using Cronbach α and intraclass correlation coefficients (2-day reliability). Convergent and known-groups validity and responsiveness were assessed using global assessments of influenza severity and return to usual health. RESULTS: Of the 536 patients enrolled, 221 influenza-positive subjects comprised the analytical sample. The mean age of the patients was 40.7 years, 60.2% were women, and 59.7% were white. The final 32-item measure has six factors/domains (nose, throat, eyes, chest/respiratory, gastrointestinal, and body/systemic), with a higher order factor representing symptom severity overall (comparative fit index = 0.92; root mean square error of approximation = 0.06). Cronbach α was high (total = 0.92; domain range = 0.71-0.87); test-retest reliability (intraclass correlation coefficient, day 1-day 2) was 0.83 for total scores and 0.57 to 0.79 for domains. Day 1 FLU-PRO domain and total scores were moderately to highly correlated (≥0.30) with Patient Global Rating of Flu Severity (except nose and throat). Consistent with known-groups validity, scores differentiated severity groups on the basis of global rating (total: F = 57.2, P < 0.001; domains: F = 8.9-67.5, P < 0.001). Subjects reporting return to usual health showed significantly greater (P < 0.05) FLU-PRO score improvement by day 7 than did those who did not, suggesting score responsiveness. CONCLUSIONS: Results suggest that FLU-PRO scores are reliable, valid, and responsive to change in influenza-positive adults.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Gripe Humana / Medición de Resultados Informados por el Paciente Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Gripe Humana / Medición de Resultados Informados por el Paciente Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article